X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bcr-abl1 (375) 375
index medicus (341) 341
humans (330) 330
chronic myeloid leukemia (252) 252
hematology (241) 241
oncology (211) 211
chronic myelogenous leukemia (190) 190
imatinib (186) 186
fusion proteins, bcr-abl - genetics (170) 170
leukemia, myelogenous, chronic, bcr-abl positive - genetics (146) 146
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (145) 145
leukemia (142) 142
chronic myeloid-leukemia (134) 134
hemic and lymphatic diseases (130) 130
male (114) 114
cml (113) 113
female (113) 113
tyrosine kinase inhibitors (111) 111
protein kinase inhibitors - therapeutic use (104) 104
adult (99) 99
middle aged (99) 99
bcr-abl (97) 97
imatinib mesylate (87) 87
aged (80) 80
tyrosine (80) 80
antineoplastic agents - therapeutic use (76) 76
dasatinib (75) 75
mutation (75) 75
philadelphia chromosome (72) 72
cancer (71) 71
analysis (67) 67
nilotinib (67) 67
tyrosine kinase inhibitor (61) 61
follow-up (60) 60
genetic aspects (60) 60
leukemia, myelogenous, chronic, bcr-abl positive - pathology (59) 59
prognosis (59) 59
bcr‐abl1 (57) 57
pyrimidines - therapeutic use (57) 57
treatment outcome (55) 55
minimal residual disease (52) 52
care and treatment (51) 51
fusion proteins, bcr-abl - metabolism (51) 51
adolescent (49) 49
chronic myeloid leukaemia (49) 49
philadelphia-chromosome (49) 49
therapy (49) 49
young adult (49) 49
research (47) 47
animals (46) 46
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (46) 46
piperazines - therapeutic use (45) 45
hematology, oncology and palliative medicine (42) 42
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (42) 42
resistance (42) 42
chronic-phase (40) 40
acute lymphoblastic-leukemia (39) 39
kinases (39) 39
medicine & public health (38) 38
patients (37) 37
aged, 80 and over (36) 36
myeloid leukemia (35) 35
polymerase chain reaction (35) 35
benzamides (34) 34
cell biology (34) 34
recommendations (34) 34
tyrosine kinase (34) 34
bcr-abl1 transcript levels (33) 33
drug resistance, neoplasm - genetics (33) 33
polymerase-chain-reaction (33) 33
protein-tyrosine kinase (33) 33
stem-cells (33) 33
diagnosis (32) 32
pathology (32) 32
precursor cell lymphoblastic leukemia-lymphoma - genetics (32) 32
stem cells (32) 32
acute lymphoblastic leukemia (31) 31
article (31) 31
bcr/abl1 (31) 31
molecular response (31) 31
protein kinase inhibitors - pharmacology (31) 31
early molecular response (30) 30
fusion proteins, bcr-abl - antagonists & inhibitors (30) 30
survival (30) 30
antineoplastic agents (29) 29
child (29) 29
drug resistance (28) 28
bcr (27) 27
drug resistance, neoplasm (27) 27
health aspects (26) 26
protein-tyrosine kinases - antagonists & inhibitors (26) 26
antimitotic agents (25) 25
blast crisis (25) 25
chromosomes (25) 25
cml patients (25) 25
diagnosed chronic-phase (25) 25
expression (25) 25
genetics & heredity (25) 25
mice (25) 25
acute lymphocytic leukemia (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (561) 561
French (10) 10
Polish (4) 4
Czech (3) 3
German (3) 3
Korean (3) 3
Spanish (3) 3
Slovenian (2) 2
Chinese (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S66 - S70
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2019, Volume 19, Issue 1, pp. 1 - 10
Abstract Background Although extensive use of tyrosine kinase inhibitors has resulted in high and durable response rate and prolonged survival time in patients... 
Clonal evolution | Prognosis | BCR-ABL1 | Fluorescence in situ hybridization
Journal Article
Leukemia Research, ISSN 0145-2126, 06/2019, Volume 81, pp. 102 - 104
Journal Article
Leukemia Research, ISSN 0145-2126, 03/2019, Volume 78, pp. 36 - 44
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in... 
BCR-ABL1 T315I | Drug combinations | Drug resistance | Bosutinib
Journal Article
Leukemia Research, ISSN 0145-2126, 03/2019, Volume 78, pp. 36 - 44
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in... 
BCR-ABL1 T315I | Drug combinations | Drug resistance | Bosutinib
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 10/2018, Volume 18, Issue 10, pp. e391 - e399
Retrospective analysis of Asian and white patients with chronic myeloid leukemia (CML) was performed to assess the frequency of BCR-ABL1 mutations in patients... 
Imatinib | CML | Drug resistance | Asian countries | BCR-ABL1 mutation
Journal Article
American Journal of Clinical Pathology, ISSN 0002-9173, 01/2019, Volume 151, Issue 1, pp. 68 - 74
Abstract Objectives As pathologists and laboratorians, we can enhance patient care by promoting the appropriate ordering of diagnostic tests. Our goal was to... 
Chronic myelogenous leukemia | Patient safety | Health care costs | Quality improvement | Electronic health records | BCR-ABL1 | PATHOLOGY
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 08/2019, Volume 60, Issue 10, pp. 2384 - 2393
ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within... 
chronic myeloid leukemia | deep molecular response | digital PCR | nilotinib | BCR-ABL1
Journal Article
by Liu, XR and Mai, HR and Jiang, HF and Xing, ZH and Peng, D and Kong, Y and Zhu, CQ and Chen, YS
BMC CANCER, ISSN 1471-2407, 07/2019, Volume 19, Issue 1, pp. 679 - 11
BackgroundAlthough the prognosis of chronic myeloid leukemia (CML) has dramatically improved, the pathogenesis of CML remains elusive. Studies have shown that... 
Cell proliferation | TONGUE | FAM168A | ONCOLOGY | BCR-ABL1 | RESISTANCE | AKT1 | Chronic myeloid leukemia
Journal Article
British journal of haematology, ISSN 0007-1048, 5/2012, Volume 157, Issue 4, pp. 507 - 510
Journal Article
Medical Journal of Malaysia, ISSN 0300-5283, 04/2018, Volume 73, Issue 2, pp. 78 - 85
There are very few published chronic myeloid leukaemia (CML) epidemiology studies in South-East Asia and no representative from Malaysia. This is a... 
Malaysia | CML | Asia | Tyrosine kinase inhibitor | Epidemiology | BCR-ABL1
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 05/2019, Volume 20, Issue 9, p. 2226
A reduction in transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical... 
chronic myeloid leukemia | European Leukemia Net | imatinib mesylate | early molecular response | BCR-ABL1
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.